Sood AK - Search Results

1

Markers of angiogenesis in ovarian cancer.

Merritt WM, Sood AK. Merritt WM, et al. Among authors: sood ak. Dis Markers. 2007;23(5-6):419-31. doi: 10.1155/2007/257602. Dis Markers. 2007. PMID: 18057525 Free PMC article. Review.

2

Ovarian cancer p53 mutation is associated with tumor microvessel density.

Goodheart MJ, Vasef MA, Sood AK, Davis CS, Buller RE. Goodheart MJ, et al. Among authors: sood ak. Gynecol Oncol. 2002 Jul;86(1):85-90. doi: 10.1006/gyno.2002.6730. Gynecol Oncol. 2002. PMID: 12079305

3

Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.

Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ, Sood AK. Cooper BC, et al. Among authors: sood ak. Clin Cancer Res. 2002 Oct;8(10):3193-7. Clin Cancer Res. 2002. PMID: 12374688

4

The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy.

Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA, Hendrix MJ. Sood AK, et al. Cancer Biol Ther. 2002 Nov-Dec;1(6):661-4. doi: 10.4161/cbt.316. Cancer Biol Ther. 2002. PMID: 12642690 Free article.

5

Functional role of matrix metalloproteinases in ovarian tumor cell plasticity.

Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM, Hendrix MJ. Sood AK, et al. Am J Obstet Gynecol. 2004 Apr;190(4):899-909. doi: 10.1016/j.ajog.2004.02.011. Am J Obstet Gynecol. 2004. PMID: 15118611

6

Fifth International Conference on Ovarian Cancer: challenges and opportunities.

Sood AK, Abu-Rustum NR, Barakat RR, Bodurka DC, Brown J, Donato ML, Poynor EA, Wolf JK, Gershenson DM. Sood AK, et al. Gynecol Oncol. 2005 Jun;97(3):916-23. doi: 10.1016/j.ygyno.2005.03.013. Gynecol Oncol. 2005. PMID: 15907981

7

The merits of vascular targeting for gynecologic malignancies.

Kamat AA, Sood AK. Kamat AA, et al. Among authors: sood ak. Curr Oncol Rep. 2005 Nov;7(6):444-50. doi: 10.1007/s11912-005-0009-x. Curr Oncol Rep. 2005. PMID: 16221381 Free PMC article. Review.

8

EphA2 as a target for ovarian cancer therapy.

Landen CN, Kinch MS, Sood AK. Landen CN, et al. Among authors: sood ak. Expert Opin Ther Targets. 2005 Dec;9(6):1179-87. doi: 10.1517/14728222.9.6.1179. Expert Opin Ther Targets. 2005. PMID: 16300469 Review.

9

Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.

Han LY, Landen CN Jr, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM, Sood AK. Han LY, et al. Among authors: sood ak. J Clin Oncol. 2006 Feb 10;24(5):755-61. doi: 10.1200/JCO.2005.02.9181. Epub 2005 Dec 27. J Clin Oncol. 2006. PMID: 16380413

10

Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.

Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Thaker PH, et al. Among authors: sood ak. Nat Med. 2006 Aug;12(8):939-44. doi: 10.1038/nm1447. Epub 2006 Jul 23. Nat Med. 2006. PMID: 16862152

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,162 results

Search Page

Filters